Limb girdle muscular dystrophy / Duchenne Muscular Dystrophy
Limb Girdle Muscular Dystrophy
Limb-Girdle Muscular Dystrophies (LGMD) are a group of muscular dystrophies, that until the late 1980s were identified in patients by ‘diagnosis by exclusion’. Revolutionary advances in molecular biology in the last several decades have allowed the scientific community to understand and recognize this disease more clearly. Currently, there are >25 LGMD types that have been linked to specific gene loci, and they are now estimated to constitute one third of all Duchenne muscular dystrophy cases.
Limb-Girdle Muscular Dystrophy is a term for a group of diseases that cause weakness and loss of the muscle mass in the legs and arms. The severity, age of onset, and functions of limb-girdle muscle dystrophy vary most of the subtypes of this condition and can be inconsistent even within the identical family. Symptoms and signs may also first appear at any age and usually get worse with time, even though in some cases they continue to be moderate. In the early stages of limb-girdle muscular dystrophy, affected people may additionally have an unusual walking gait, including waddling or walking at the balls in their feet, and can also have a problem in running. they may want to use their arms to press themselves up from a squatting position due to their vulnerable thigh muscle mass. because the circumstance progresses, humans with limb-girdle muscular dystrophy may sooner or later require wheelchair assistance.
Stem Cell Therapy for Limb Girdle Muscular Dystrophy
Scientists have proved that our body has distinct sources of stem cells in different organs which aren't being used by them. These sources of stem cells can now be exploited to isolate rich population of stem cells which when infused into the muscles can replace the damaged muscle cells with wholesome muscular fibres and decreased the inflammation related to the muscular dystrophy thereby slowing the development of the disease.
Duchenne Muscular Dystrophy (DMD)
Duchenne Muscular Dystrophy (DMD) is an X-linked recessive genetic disease. Worldwide, around 1 in 3500 boys suffer from DMD. The child is usually normal at birth but the disease onsets around 3 years of age. Initially, the child starts feeling difficulty in getting up from the ground which is accompanied by frequent falling on brisk walking. Gradually, the problem going on increasing in the form of calf muscle enlargement with inability to climb the staircase. In the following time, all the muscles of the body starts to lose power and the child is bed-ridden between the age of 8-10 years. In most cases, death occurs between 14 to 21 years due to respiratory or cardiac failure. DMD results due to deficiency of a protein called dystrophin in the muscle cells.
However, Stem Cell Treatment for Duchenne Muscular Dystrophy now offers hope. Like any other degenerative disorders, DMD is the result of the loss of cells which are required for the proper functioning of the body. In the case of DMD, a vital muscle protein is mutated, and its absence results in progressive degeneration of essentially all of the muscles in the body.